KPV 10mg

Researchers evaluating KPV can compare the supplier listing with its analytical documentation and research-use-only labeling. KPV is commonly described as MSH(11-13), the lysine-proline-valine tripeptide associated with the C-terminal portion of alpha-melanocyte-stimulating hormone [1] [2] . This guide covers identity, literature interpretation, melanocortin receptor context, COA assessment, and laboratory procurement.

• KPV is a short peptide entity listed by PubChem as MSH(11-13), with the synonym Lys-Pro-Val and the formula C16H30N4O4 [1].
• The KPV peptide is discussed in literature as a peptide fragment connected to alpha-melanocyte-stimulating hormone, which is derived from the POMC precursor system [2][3].
• Research buyers should review RUO labeling, certificate of analysis records, peptide purity data, identity testing, lot traceability, and supplier documentation before procurement.
• Literature on KPV includes melanocortin, receptor, inflammatory pathway, cytokine, NF-κB, intestinal epithelium, and in vitro laboratory research contexts, but those findings must remain separate from product claims [9][14][16].
• Analytical review should distinguish purity testing from identity verification; HPLC and LC-MS address related but different documentation questions [21][23].

Fast Answer: What Should Researchers Check Before They Buy KPV for Research?

To buy KPV for research responsibly, researchers should first review the compound identity, RUO label, batch-specific certificate of analysis, HPLC purity data, LC-MS identity support, lot number, storage notes, and supplier documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Literature context should not be converted into product-use claims.

KPV identity and documentation review

Laboratory teams evaluating where to buy KPV for research should verify compound identity, analytical purity, lot traceability, and research-use-only labeling against the available batch records.

This distinction matters because KPV appears in both compound databases and experimental literature. PubChem lists MSH(11-13) with KPV-related synonyms, molecular formula, and molecular weight fields, while academic papers examine pathway-level questions in specific models [1][14].

What Documentation Should Come First?

Start with the label, certificate of analysis, and lot-specific records. A certificate of analysis should make it possible to connect the product listing, batch identity, purity measurement, and analytical method in one review trail. FDA analytical-method guidance describes analytical procedures as tools for documenting identity, quality, purity, and related measurements in regulated-material contexts, which is useful as a general quality framework for documentation review [25].

The safest procurement order is simple: label first, COA second, analytical data third, traceability fourth. If the product name, lot number, and COA do not align, the page is not documentation-ready.

Why Should RUO Labeling Come Before Procurement?

RUO labeling sets the scope for the page. FDA’s RUO/IUO guidance is written for in vitro diagnostic products, but it is still a useful example of how research labeling and intended scope should be aligned with presentation [28]. Federal IVD labeling rules also show that research labeling is tied to restricted research positioning rather than broad product claims [29].

Published studies describe experimental observations, not established effects of the listed product.

Research-Use-Only Limits for KPV

Laboratory buyers can compare COAs, lot records, analytical results, and supplier notes. These records support research procurement, not consumer use.

Laboratory Research Use

Research use means the material is positioned for laboratory research use, not as a food, cosmetic, household item, dietary supplement, or clinical product. For KPV, that positioning should be paired with compound identity, peptide purity, and analytical testing information.

FDA, EMA, USP, and ICH documents provide analytical-quality or documentation frameworks [24] [27] . Their inclusion does not establish that an RUO peptide is approved, standardized, or suitable for another use category.

What Is KPV in Research Literature?

KPV is the lysine-proline-valine tripeptide associated with MSH(11-13), a short C-terminal peptide fragment linked to alpha-MSH literature [1][2]. PubChem lists MSH(11-13) with molecular formula C16H30N4O4 and molecular weight 342.43 g/mol [1].

Confirm the identity of the material studied before interpreting pathway findings.

KPV Peptide Identity and Tripeptide Classification

A tripeptide contains three amino acid residues. For KPV, those residues are lysine, proline, and valine, which explains the common Lys-Pro-Val shorthand [1]. PubChem also identifies MSH(11-13) with KPV-related names, giving research buyers a database-backed identity checkpoint [1].

How Does Lysine-Proline-Valine Define the Sequence?

Lysine-proline-valine defines the KPV sequence in plain language. Lysine supplies the “K,” proline supplies the “P,” and valine supplies the “V.” PubChem’s MSH(11-13) entry supports that sequence-level identity [1].

Sequence matters because many peptide documentation errors start with naming mismatches.

Where Does KPV Fit Within A-MSH Fragment Research?

KPV is commonly discussed as a C-terminal alpha-MSH fragment. Alpha-melanocyte-stimulating hormone is listed by PubChem as a thirteen amino acid peptide hormone, and UniProt identifies melanocyte-stimulating hormone alpha as part of the pro-opiomelanocortin system [2][3].

This relationship explains why KPV literature intersects with melanocortin peptides, receptor signaling, and inflammatory pathway models. It does not establish effects of the listed material.

Alpha-MSH and A-MSH Fragment Context

Alpha-MSH is a melanocortin peptide derived from POMC processing, and UniProt describes alpha-MSH as a ligand for melanocortin receptors including MC1R, MC3R, MC4R, and MC5R [3]. KPV is linked to the final portion of alpha-MSH, which is why it appears in alpha-MSH fragment research [1][2].

This context helps researchers interpret the literature.

Melanocortin Peptide Research Context

The melanocortin receptor system includes five closely related G-protein-coupled receptors, commonly described as MC1R through MC5R [7][8]. Reviews describe melanocortin peptides as ligands that interact with this receptor family across different cell and signaling contexts [7][9].

Relevant KPV background includes alpha-MSH fragment studies, melanocortin receptor signaling, NF-κB models, cytokine measurements, and peptide identity testing.

Mechanism of Action Context in KPV Literature

KPV literature includes several mechanistic themes, including melanocortin-related context, PepT1-mediated uptake in intestinal epithelial and immune cells, and NF-κB signaling models [12][14][16].

What Can Mechanistic Papers Show About KPV?

Mechanistic papers can show how a model was designed, what pathway markers were measured, and what observations were reported. For example, one KPV study examined whether the peptide’s activity in intestinal epithelial cells and immune cells was associated with the peptide transporter PepT1 [14]. Another paper investigated KPV and alpha-MSH-related signaling in airway epithelial cell models, including NF-κB-linked measurements [16].

Those findings apply to the experimental models studied; they do not establish effects of this RUO material.

Melanocortin Receptor Signal Pathway Overview

Melanocortin receptors are class A GPCRs, and reviews describe the receptor family as MC1R, MC2R, MC3R, MC4R, and MC5R [7][8]. NCBI Gene describes MC1R as encoding a seven-pass transmembrane G-protein-coupled receptor for melanocyte-stimulating hormone [4]. UniProt similarly identifies MC1R as a receptor that binds melanocyte-stimulating hormones and ACTH [5].

Some papers have explored whether KPV-related observations are MC1R or cyclic-AMP dependent, while later work examined alternate cellular mechanisms [12] [16] . Interpret each proposed mechanism within its study model.

What Does Pathway Relevance Establish?

A signal pathway can be relevant to a research model without becoming a product claim. NF-κB, cytokine, and inflammatory gene expression markers are common in mechanistic literature [16][17].

Pathway relevance identifies what a study examined, not what a catalog product does.

KPV Receptor Research and Cell Signaling Models

KPV studies overlap melanocortin receptor biology and cell signaling research. MC1R, MC3R, and related receptor contexts appear in the broader alpha-MSH literature [6] [7] [9] .

Evaluate these links separately from the lot-specific evidence identifying and characterizing the supplied material.

Which Melanocortin Receptor Contexts Are Relevant?

MC1R is the most common receptor entity connected to alpha-MSH identity and melanocortin receptor discussion, and the Guide to Pharmacology lists MC1 receptor nomenclature and database links for the receptor target [6]. Broader reviews explain that melanocortin receptors differ by subtype, ligand interaction, tissue expression, and downstream signaling features [7][8].

KPV-specific literature is more cautious. Elliott and colleagues examined KPV and related C-terminal tripeptides while noting that the exact dependence on MC1R or cyclic AMP required clarification [12].

Cytokine and Gene-Expression Readouts

KPV papers have used cytokine and gene-expression-related markers as model readouts. In the PepT1 study, researchers examined KPV in intestinal epithelial and immune cells, including inflammatory signaling readouts [14]. In airway epithelial research, KPV was examined alongside NF-κB reporter activity and chemokine measurements [16].

These are model-specific measurements, not established effects of the listed KPV material.

Inflammatory Pathway Research Context for KPV

Alpha-MSH and related peptides have been examined in inflammation-related research models [9] [10] [11] . This provides background for interpreting KPV studies within their experimental conditions.

In Vitro Models and Intestinal Epithelium Context

In vitro research is useful because it lets investigators examine defined cell systems and pathway markers under controlled conditions. The PepT1 KPV paper examined intestinal epithelial cells and immune cells, connecting KPV uptake to transporter expression in that model context [14]. A separate review describes PepT1 as a membrane transporter relevant to epithelial peptide transport biology [19].

The intestinal epithelium is an experimental model in this literature, not an intended-use indication for the supplied material.

How Should Published Literature Be Interpreted?

Published literature should be interpreted by source type, model type, endpoint, and limitation. A database entry can support compound identity. A review can summarize a field. A mechanistic study can report pathway observations. None of these automatically becomes a product claim.

What Study Type Should Researchers Identify First?

Research buyers should identify whether a source is a database entry, review, in vitro paper, preclinical paper, analytical chemistry article, or official documentation standard. Each source type answers a different question.

For KPV, PubChem answers identity questions [1]. Melanocortin reviews answer receptor-family and pathway-context questions [7][9]. Analytical sources answer documentation and testing questions [21][23][24].

Why Do Preclinical Findings Require Careful Limits?

Preclinical findings depend on model design, assay conditions, and endpoints. KPV has been examined in preclinical inflammatory pathway studies and reviews [15] [20] . These sources do not establish effects or suitability of the listed material.

Evidence Quality Signals for Researchers

Good evidence signals include a peer-reviewed source, clear model description, defined endpoints, analytical methods, and cautious interpretation. Strong product-page documentation also includes COA availability, method naming, batch match, lot date, and storage notes.

Separating Study Results From Product Documentation

Study results concern specific experimental materials and conditions; supplier records concern the material and lot offered.

What Does a Study Finding Establish?

Study findings are tied to the conditions of the study. A paper may examine cytokine markers, NF-κB signaling, receptor context, or intestinal epithelium models [14][16].

What Is the Scope of the Listed Material?

KPV is supplied as a laboratory research material, not a consumer product.

Why Does Certificate of Analysis Review Matter for KPV?

A certificate of analysis matters because it connects the product listing to batch-specific analytical information. FDA analytical-method guidance identifies analytical procedures as part of documentation for identity, quality, purity, and related measurements in regulated contexts [25]. USP discussion of reference-standard certificates also emphasizes lot-specific certificate access and assigned-value documentation for reference standards [30].

For RUO KPV, the COA should be reviewed as a documentation record. It is not a guarantee of every possible quality attribute.

What Should a Certificate of Analysis Include?

A useful COA should identify the compound name, batch or lot number, test date, reported purity, analytical method, and supplier or laboratory source. If identity testing is listed, the method should be clear enough for technical review.

For a peptide, documentation is stronger when purity and identity are supported by complementary methods. Synthetic peptide guidance and reference-standard literature often emphasize multiple quality attributes, including identity, purity, impurities, and method suitability [22][27].

How Batch-Specific Documentation Supports Review

Batch-specific documentation reduces ambiguity. A COA that does not match the product lot creates a gap between the listing and the record.

Researchers should compare the KPV name, lot number, COA date, and analytical method across the product page and supplier documentation. A match does not replace scientific review, but it gives the procurement record a traceable structure.

Why COA Dates and Lot Numbers Matter

COA dates and lot numbers help researchers understand which material the record describes. USP certificate policy for reference standards discusses current and previous lots, which illustrates why lot status and certificate timing matter in technical documentation [30].

For KPV research procurement, the key question is whether the label, COA, and supplier notes describe the same batch.

Peptide Purity and Identity Testing Considerations

Peptide purity and peptide identity are related, but they are not identical. HPLC can support purity review by separating peptide-related peaks, while mass spectrometry can support identity review by measuring mass-related information [21][23].

The strongest documentation uses method detail. A simple purity percentage without method context is not enough for a complete technical review.

How HPLC Supports Peptide Purity Review?

HPLC is widely used for peptide analysis and purification because chromatographic separation can show the relative presence of a main peak and related peaks under defined conditions [21]. In synthetic peptide reference-standard work, RP-HPLC has been used to assess lot homogeneity, stability, identity-related attributes, content, and purity [22].

How LC-MS Supports KPV Identity Verification?

LC-MS can support identity verification because it combines liquid chromatography with mass spectrometry, allowing mass-related information to be reviewed with separation behavior [23]. ICH Q2(R2) also describes analytical-procedure validation concepts for identity, purity, impurity, assay, and other quantitative or qualitative measurements [24].

A safe lab-test verification workflow can follow this order:

1. Verify that the compound name, KPV, MSH(11-13), and lot number match across the label and documents.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity method is listed, such as HPLC.
4. Confirm whether identity testing is supported by LC-MS or another suitable analytical method.
5. Review chromatogram or mass-data summaries when available.
6. Check the COA date and the stated laboratory or supplier source.
7. Record storage and handling requirements in the laboratory documentation file.

Lot Traceability and Batch Documentation Review

Lot traceability lets researchers connect the physical research material to a documentation trail. In peptide procurement, traceability is practical: it helps organize the product listing, COA, testing data, label, and storage notes.

It also supports internal review. A lab team can confirm whether the record set is complete before adding the material to its laboratory inventory.

What Does Lot Traceability Add to Research Procurement?

Lot traceability adds continuity. It lets the research buyer ask whether the product page, COA, HPLC record, LC-MS record, and label all refer to the same batch.

That continuity is especially important for short peptides like KPV because small naming variations can create confusion. PubChem lists MSH(11-13), Lys-Pro-Val, and related synonyms, which makes name matching a real documentation task [1].

Storage and Handling Documentation Checkpoints

Storage and handling documentation should be treated as a laboratory record issue.

Good documentation does not only say what the product is. It also says how the supplier expects the research material to be maintained before evaluation in laboratory workflows.

Supplier Documentation Review for Verified Peptides

Verified peptides should be reviewed through documentation rather than slogans. The strongest pages provide RUO labeling, compound identity, certificate of analysis access, purity method details, identity testing support, and lot-level traceability.

Official quality frameworks also emphasize method suitability and documentation. FDA and ICH documents describe analytical-method validation principles, while EMA’s synthetic peptide guideline addresses characterization, specifications, and analytical control for synthetic peptides [24][25][27].

What Should Research Buyers Compare Across Suppliers?

Research buyers should compare the same categories across suppliers: RUO label clarity, KPV identity, COA availability, lot number match, HPLC data, LC-MS support, storage documentation, and supplier transparency.

Price alone is not a documentation metric. The better question is whether the listing gives enough technical information to support a defensible laboratory procurement record.

How Should Researchers Evaluate Online KPV Listings?

Check that the listing clearly identifies KPV, provides access to COA and analytical records, and states the research-use-only limitation.

Common Misunderstandings in KPV Evaluation

Distinguish scientific literature, supplier claims, and lot-specific product documentation when evaluating KPV.

Common misunderstandings include:

• Published literature does not establish effects of the listed material.
• Preclinical findings should not become broad conclusions.
• A purity percentage does not prove complete compound identity.
• A COA should be batch-specific and tied to a lot number.
• Catalog formats are listing details, not research conclusions.

KPV Research Procurement Checklist

Use this checklist to verify the documentation trail before selecting KPV for laboratory research.

• Verify that the compound is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by an identified analytical method.
• Check that the lot number on the COA matches the product documentation.
• Compare KPV, MSH(11-13), Lys-Pro-Val, and sequence references where supplied.
• Assess whether the product page avoids out-of-scope claims.
• Document storage and handling conditions in a laboratory record.
• Preserve COA, chromatogram, mass-data summaries, and supplier notes with the procurement file.

What Should Be Confirmed Before Researchers Buy KPV Peptide for Research?

What is the compound? What batch does the COA describe? Which analytical methods support the record? Does the page maintain RUO scope?

If those questions are answered clearly, the procurement review is stronger. If they are not, the page needs closer scrutiny.

Where Do COAs and Supplier Notes Fit Together?

COAs and supplier notes should form one documentation set. The COA provides analytical data. Supplier notes provide label, storage, and handling context. The product listing connects both to the research material.

For KPV, the best documentation record is consistent across all three: product page, COA, and supplier notes.

Next Steps for RUO Procurement Review

Review the identity records, COA, analytical testing, lot traceability, supplier documentation, and RUO labeling before selecting KPV for laboratory research.

FAQs

What does research use only mean for KPV?

Research use only means KPV is intended solely for laboratory research contexts. This designation ensures that the compound is handled under controlled experimental conditions, with documentation such as COA, lot traceability, and analytical testing confirming identity and purity. It is not intended for human or animal consumption, and all interpretations must remain within preclinical and in vitro research boundaries.

Why do researchers review COAs for KPV?

Researchers review a Certificate of Analysis (COA) for KPV because it provides batch-specific documentation, including purity, peptide identity, and analytical testing methods such as HPLC or LC-MS. Evaluating COAs ensures that the laboratory material aligns with the labeled compound and supports reproducible research results without extrapolating to human or animal use.

How should published literature be interpreted for KPV research materials?

Published literature should be interpreted as research context, not as guidance for product use. For KPV, studies often examine receptor pathways, peptide signaling, or in vitro models. Researchers should distinguish between experimental findings and product claims, focusing on compound characterization, pathway analysis, and peer-reviewed methodology.

What analytical methods are used to evaluate KPV purity and identity?

Analytical methods for KPV include high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS). These techniques confirm peptide identity, verify purity, and match the experimental batch to documentation. Proper application of these methods ensures reliable research-use-only verification without implying any human or animal use.

Why does lot traceability matter for KPV research materials?

Lot traceability is critical for KPV because it connects the product to specific COAs, analytical testing, and documentation records. Maintaining traceability allows researchers to confirm that experimental results are reproducible and attributable to a verified peptide batch, supporting laboratory and research integrity.

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Didier Merlin

Author profile: Georgia State University Profile

Didier Merlin’s coauthored publications concern KPV, PepT1, intestinal epithelium, and peptide transport. They provide model-specific context for transporter and pathway research. Evaluate mechanistic findings separately from the analytical verification and batch records for the listed material.

Selected publications:

• A peer-reviewed KPV and PepT1 research model study — Gastroenterology, 2008. PMID: [18061177]
• A review of PepT1 transporter literature relevant to peptide transport models — American Journal of Physiology—Gastrointestinal and Liver Physiology, 2012. PMID: [22194420]

Thomas A. Luger

Author profile: University of Münster Research Portal

Thomas A. Luger’s publications concern alpha-MSH-derived tripeptides, melanocortin receptor pathways, and cytokine-model findings. These sources provide background for interpreting KPV in melanocortin peptide research, not evidence of effects or consumer suitability of this catalog material.

Selected publications:

• A review of alpha-MSH related peptide literature — Ann Rheum Dis., 2007. PMID: [17934097]
• A review relevant to alpha-MSH tripeptide biochemistry and melanocortin receptor literature — Endocrine Reviews, 2008. DOI: 10.1210/er.2007-0027

REFERENCES

1. PubChem. MSH(11-13) compound identity record. National Center for Biotechnology Information. 2026 database record.
2. PubChem. Alpha-melanocyte-stimulating hormone compound identity record. National Center for Biotechnology Information. 2026 database record.
3. UniProt Consortium. POMC — Pro-opiomelanocortin, Homo sapiens. UniProtKB. 2026 database record.
4. NCBI Gene. MC1R melanocortin 1 receptor gene record. National Center for Biotechnology Information. Updated 2026.
5. UniProt Consortium. MC1R — melanocyte-stimulating hormone receptor. UniProtKB. 2026 database record.
6. IUPHAR/BPS Guide to Pharmacology. MC1 receptor target record. Guide to Pharmacology database.
7. Cai M, Hruby VJ. The melanocortin receptor system: research overview. Current Protein & Peptide Science. 2016. PMID: 26916163.
8. Yang Y. Structure, function and regulation of melanocortin receptors. European Journal of Pharmacology. 2011. PMID: 21208602.
9. Wang W, Guo DY, Lin YJ, Tao YX. Melanocortin regulation of inflammation. Frontiers in Endocrinology. 2019. PMID: 31649521.
10. Luger TA, Brzoska T, Scholzen TE, et al. Alpha-MSH related peptide research review. Annals of the New York Academy of Sciences. 2007. PMID: 17934097.
11. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-MSH and related tripeptide research review. Endocrine Reviews. 2008. PMID: 18612139.
12. Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. Alpha-MSH C-terminal tripeptide KPV receptor-context study. The Journal of investigative dermatology. 2004. PMID: 15102092.
13. Getting SJ, et al. MSH peptide comparison in inflammatory pathway research models. The Journal of pharmacology and experimental therapeutics. 2003. PMID: 12750433.
14. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. KPV transporter-mediated uptake in epithelial and immune-cell research models. Gastroenterology. 2008. PMID: 18061177.
15. Kannengiesser K, Maaser C, Heidemann J, et al. KPV in preclinical colonic inflammatory pathway models. Inflammatory Bowel Diseases. 2008. PMID: 18092346.
16. Land SC, Scott CL, Walker D. KPV mechanism research and MC3R agonist context. International Journal of Physiology, Pathophysiology and Pharmacology. 2012. PMID: 22837805.
17. Manna SK, Aggarwal BB. Alpha-MSH and NF-κB signaling research. Journal of Immunology. 1998. PMID: 9743348.
18. Fagerlund R, Kinnunen L, Köhler M, Julkunen I, Melén K. Importin alpha-3 and NF-κB nuclear transport research. Journal of Biological Chemistry. 2005. PMID: 15677444.
19. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D. PepT1 membrane transporter research review. Inflammatory Bowel Diseases. 2012. PMID: 22005814.
20. Gravina AG, Pellegrino R, Dallio M, et al. Melanocortin system research in intestinal inflammatory pathway literature. Cells. 2023. PMID: 37508378.
21. Mant CT, Chen Y, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. PMID: 18369942.
22. McCarthy D, Tan C, Kulkarni S, et al. Reference standards supporting synthetic peptide quality. AAPS Open. 2023. PMID: 37426312.
23. Zeng K, Geerlof-Vidavsky I, Gucinski A, Jiang X, Boyne MT. LC-HRMS for peptide identification and impurity characterization. The AAPS Journal. 2015. PMID: 25739786.
24. International Council for Harmonisation. Q2(R2) validation of analytical procedures. ICH Harmonised Guideline. 2023.
25. U.S. Food and Drug Administration. Analytical procedures and methods validation guidance. FDA Guidance. 2015/2020 web record.
26. U.S. Food and Drug Administration. Q7A good manufacturing practice guidance for active pharmaceutical ingredients. FDA Guidance. 2018 web record.
27. European Medicines Agency. Development and manufacture of synthetic peptides scientific guideline. EMA Scientific Guideline. 2025.
28. U.S. Food and Drug Administration. Research-use-only and investigational-use-only labeling guidance for IVD products. FDA Guidance. 2013/2018 web record.
29. Electronic Code of Federal Regulations. 21 CFR Part 809 — In vitro diagnostic products. U.S. Government Publishing Office / eCFR. Current regulation.
30. United States Pharmacopeia. USP reference standard certificates and assigned values policy statement. USP. 2020.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.